ReviewThe European journal of neuroscience2026
Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon.
Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon.The European journal of neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Freezing of gait (FoG) is an episodic, debilitating motor phenomenon defined as paroxysmal episodes wherein there is an inability to step effectively, despite attempting to do so. Although FoG is most commonly associated with Parkinson's disease, it manifests across a spectrum of progressive neurodegenerative and potentially transient non-neurodegenerative conditions that affect overlapping locomotor circuits. The episodic nature of FoG implies transient disruptions of a distributed locomotor network rather than fixed structural lesions, rendering its neuropathological basis particularly challenging to define. This review synthesizes current knowledge of the structural, neurochemical and proteinopathic substrates that precondition and precipitate FoG. The principal disease categories implicated in FoG are reviewed, including Lewy body diseases, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration and argyrophilic grain disease, as well as non-neurodegenerative conditions such as cerebrovascular disease and metabolic encephalopathy. Mixed and overlapping pathologies are common. Across these disorders, different disease stages and phases, and their frequent combinations, interact with selective vulnerability of distinct neuronal and glial populations, giving rise to a complex pathophysiological landscape. It is proposed that this convergence results in heightened network susceptibility, whereby cumulative damage to cortical, subcortical and brainstem locomotor nodes progressively lowers the threshold for episodic circuit failure. Understanding these multilevel neuropathological determinants is essential for developing targeted therapeutic strategies aimed at stabilizing the locomotor network and reducing FoG burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.